What 4 Analyst Ratings Have To Say About Bluebird Bio
What 4 Analyst Ratings Have To Say About Bluebird Bio
关于bluebird bio有4个分析师评级，以下是他们的评价。
4 analysts have expressed a variety of opinions on bluebird bio (NASDAQ:BLUE) over the past quarter, offering a diverse set of opinions from bullish to bearish.
过去一季度，4位分析师对bluebird bio（纳斯达克:BLUE）发表了各种各样的意见，从看好到看淡不一。
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
总结他们最近的评估，下表展示了过去30天内不断变化的情绪，并将其与之前的几个月进行了比较。
The 12-month price targets, analyzed by analysts, offer insights with an average target of $4.25, a high estimate of $6.00, and a low estimate of $3.00. A decline of 26.09% from the prior average price target is evident in the current average.
经过分析师的分析，12个月的目标股价给出了洞察力，平均目标价为$4.25，高估值为$6.00，低估值为$3.00。与先前的平均价格目标相比，当前平均目标价下降了26.09%。
Exploring Analyst Ratings: An In-Depth Overview
分析师评级:深入了解
In examining recent analyst actions, we gain...
通过检查最近的...
登录免费看全文
登录/注册